59 related articles for article (PubMed ID: 31821385)
1. [Comparison of therapeutic peptides targeting pancreatic cancer].
Mezõ G; Dókus L; Schlosser G; Lajkó E; Szász Z; Ranđelović I; Biri-Kovács B; Tóvári J; Kõhidai L
Magy Onkol; 2019 Dec; 63(4):301-308. PubMed ID: 31821385
[TBL] [Abstract][Full Text] [Related]
2. Phage Display-Based Homing Peptide-Daunomycin Conjugates for Selective Drug Targeting to PANC-1 Pancreatic Cancer.
Dókus LE; Lajkó E; Ranđelović I; Mező D; Schlosser G; Kőhidai L; Tóvári J; Mező G
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32580307
[TBL] [Abstract][Full Text] [Related]
3. Sequence modification of heptapeptide selected by phage display as homing device for HT-29 colon cancer cells to improve the anti-tumour activity of drug delivery systems.
Kiss K; Biri-Kovács B; Szabó R; Ranđelović I; Enyedi KN; Schlosser G; Orosz Á; Kapuvári B; Tóvári J; Mező G
Eur J Med Chem; 2019 Aug; 176():105-116. PubMed ID: 31100648
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of the cell and molecular biological effect of peptide-based daunorubicin conjugates developed for targeting pancreatic adenocarcinoma (PANC-1) cell line.
Szász Z; Enyedi KN; Takács A; Fekete N; Mező G; Kőhidai L; Lajkó E
Biomed Pharmacother; 2024 Apr; 173():116293. PubMed ID: 38430628
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Tumor Growth Inhibition and Antiangiogenic Effect of Cyclic NGR Peptide-Daunorubicin Conjugates Developed for Targeted Drug Delivery.
Tripodi AAP; Ranđelović I; Biri-Kovács B; Szeder B; Mező G; Tóvári J
Pathol Oncol Res; 2020 Jul; 26(3):1879-1892. PubMed ID: 31820302
[TBL] [Abstract][Full Text] [Related]
6. Drug targeting to decrease cardiotoxicity - determination of the cytotoxic effect of GnRH-based conjugates containing doxorubicin, daunorubicin and methotrexate on human cardiomyocytes and endothelial cells.
Polgár L; Lajkó E; Soós P; Láng O; Manea M; Merkely B; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():1583-1594. PubMed ID: 30013686
[No Abstract] [Full Text] [Related]
7. Comparative cell biological study of in vitro antitumor and antimetastatic activity on melanoma cells of GnRH-III-containing conjugates modified with short-chain fatty acids.
Lajkó E; Spring S; Hegedüs R; Biri-Kovács B; Ingebrandt S; Mező G; Kőhidai L
Beilstein J Org Chem; 2018; 14():2495-2509. PubMed ID: 30344773
[No Abstract] [Full Text] [Related]
8. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer.
Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S
PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622
[TBL] [Abstract][Full Text] [Related]
9. In-vivo antitumour effect of daunorubicin-GnRH-III derivative conjugates on colon carcinoma-bearing mice.
Manea M; Tóvári J; Tejeda M; Schulcz A; Kapuvári B; Vincze B; Mezo G
Anticancer Drugs; 2012 Jan; 23(1):90-7. PubMed ID: 21915040
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
[TBL] [Abstract][Full Text] [Related]
11. Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.
Mohammad RM; Adsay NV; Philip PA; Pettit GR; Vaitkevicius VK; Sarkar FH
Anticancer Drugs; 2001 Oct; 12(9):735-40. PubMed ID: 11593055
[TBL] [Abstract][Full Text] [Related]
12. Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models.
Chau Y; Padera RF; Dang NM; Langer R
Int J Cancer; 2006 Mar; 118(6):1519-26. PubMed ID: 16187287
[TBL] [Abstract][Full Text] [Related]
13. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
14. Combination of active targeting, enzyme-triggered release and fluorescent dye into gold nanoclusters for endomicroscopy-guided photothermal/photodynamic therapy to pancreatic ductal adenocarcinoma.
Li H; Wang P; Deng Y; Zeng M; Tang Y; Zhu WH; Cheng Y
Biomaterials; 2017 Sep; 139():30-38. PubMed ID: 28582716
[TBL] [Abstract][Full Text] [Related]
15. New somatostatin-drug conjugates for effective targeting pancreatic cancer.
Ragozin E; Hesin A; Bazylevich A; Tuchinsky H; Bovina A; Shekhter Zahavi T; Oron-Herman M; Kostenich G; Firer MA; Rubinek T; Wolf I; Luboshits G; Sherman MY; Gellerman G
Bioorg Med Chem; 2018 Jul; 26(13):3825-3836. PubMed ID: 30017114
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mononuclear cells.
Uchida D; Shiraha H; Kato H; Sawahara H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Takaki A; Nouso K; Nasu Y; Kumon H; Yamamoto K
J Gastroenterol Hepatol; 2016 Jun; 31(6):1154-9. PubMed ID: 26643412
[TBL] [Abstract][Full Text] [Related]
17. Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.
Kapuvári B; Hegedüs R; Schulcz Á; Manea M; Tóvári J; Gacs A; Vincze B; Mező G
Invest New Drugs; 2016 Aug; 34(4):416-23. PubMed ID: 27146514
[TBL] [Abstract][Full Text] [Related]
18. Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.
Ohman KA; Hashim YM; Vangveravong S; Nywening TM; Cullinan DR; Goedegebuure SP; Liu J; Van Tine BA; Tiriac H; Tuveson DA; DeNardo DG; Spitzer D; Mach RH; Hawkins WG
Oncotarget; 2016 Jun; 7(23):33529-41. PubMed ID: 27244881
[TBL] [Abstract][Full Text] [Related]
19. [Application of Asn-Gly-Arg sequence based cyclic peptides for targeted tumor therapy].
Mező GM; Tripodi Angelo Pierluigi ATAP; Ranđelovič IR; Enyedi NKE; Biri-Kovács BB; Tóvári JT
Magy Onkol; 2021 Jun; 65(2):113-120. PubMed ID: 34081759
[TBL] [Abstract][Full Text] [Related]
20. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
